These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9830626)

  • 1. The oral fluorouracil prodrugs.
    Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral fluoropyrimidines in colorectal cancer.
    Van Cutsem E; Peeters M
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):91-5. PubMed ID: 11049039
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fluoropyrimidine treatment of colorectal cancer.
    Eng C; Kindler HL; Schilsky RL
    Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal cancer: chemotherapy treatment overview.
    Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
    Lima AP; del Giglio A
    Eur J Cancer Care (Engl); 2005 May; 14(2):151-4. PubMed ID: 15842464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
    Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
    Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
    Hosokawa A
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():352-5. PubMed ID: 14574911
    [No Abstract]   [Full Text] [Related]  

  • 13. Answering patients' needs: oral alternatives to intravenous therapy.
    Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
    Oncologist; 2001; 6 Suppl 4():12-6. PubMed ID: 11585969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
    Hoff PM
    Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoropyrimidines: a critical evaluation.
    Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
    Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UFT/leucovorin vs 5-FU/leucovorin in colon cancer.
    Smith RE; Lembersky BC; Wieand HS; Colangelo L; Mamounas EP
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):24-7. PubMed ID: 11098486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.